E489 Jason Park, CEO at Empress Therapeutics

Today's guest is Jason Park, CEO at Empress Therapeutics. Founded by Flagship Pioneering in 2020, Empress makes the discovery of effective, easy-to-take, value-driven medicines more productive with a platform that finds starting points for drugs inside the human body. The company built a proprietary product platform called Chemilogics to canvass the untapped universe within the human body of chemistry encoded in DNA and pioneer a new paradigm in small molecule drug discovery with tremendous potential value to patients and society.

Empress ask big questions in pursuit of novel solutions. They operate at the intersection of the latest advances in genomics, synthetic biology and AI/ML with the expectation that these disciplines, harnessed by their ingenuity, hold the answers to finding effective medicines at a fraction of time and cost. The implications of the team's work will be profound and the journey to get there will be exhilarating. Together, Empress are using the chemistry inside each of their employees to make medicines for all of us.

In today's episode, Jason talks about:

His background and overview of Empress Therapeutics

An insight into Flasgship Pioneering,

The impact of small molecule research in future therapeutics,

How AI decodes DNA for compound predictions,

How the platform created 15 drug leads in 12 months,

Key team members behind their success,

Their focus on swift drug lead generation from genetic data,

Why to consider a career with Empress Therapeutics